Background/Aims: Current practical advances in high-throughput data technologies including RNA-sequencing have led to the identification of long non-coding RNAs (lncRNAs) for potential clinical application against bladder urothelial cancer (BLCA). However, most previous studies focused on the clinical value of individual lncRNAs, which has limited the potential for future clinical application. Methods: In this study, RNA-sequencing data of lncRNAs was downloaded from The Cancer Genome Atlas database. Risk score was constructed based on survivalassociated lncRNAs identified using differential expression analysis as well as univariate and multivariate Cox proportional hazards regression analysis. Receiver operating characteristic and Kaplan-Meier curve analyses were employed to evaluate the clinical and prognostic value of risk scores. Bioinformatics analyses were used to investigate the potential mechanisms of newly identified lncRNAs. Results: Among 2,127 differentially expressed lncRNAs (DELs), four new lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) showed valuable prognostic effects in BLCA patients. More importantly, the four-DEL-based risk score had the potential to become an independent marker for the survival status prediction of BLCA patients. Distinct co-expressed genes and signaling pathways were identified when BLCA was categorized into low-and high-risk groups. Furthermore, a protein-coding gene, HIST4H4 was found only 68 bp from the AC010168.2 DEL. HIST4H4 expression level was evidently upregulated and positively correlated with AC010168.2 in BLCA patients. Conclusion: This in silico investigation pioneers the future investigation of the utility of prognostic lncRNAs for BLCA.
Introduction
Bladder urothelial cancer (BLCA) is the fourth most common cancer in males and the eleventh most common cancer in females, with more than 430, 000 cases worldwide every year [1] . According to the latest epidemiological data of bladder cancer in the United States, there were an estimated 79, 030 new cases in 2017, including 60, 490 males and 18, 540 females; 16, 870 patients died, comprising 12, 240 males and 4, 630 females [2] . The incidence and mortality of male patients with BLCA was respectively 4.1 and 3.5 times higher than those of females based on data from 2009 to 2013 [2] . In China, BLCA was the thirteenth most common cancer with a total number of 80, 500 cases in 2015 [3] . The mechanisms of BLCA however remain largely unclear, which has led to the paucity of specific biomarkers for screening, surveillance, or prognostic stratification of BLCA [4] [5] [6] [7] [8] [9] [10] . Hence, there is an urgent need to identify new reliable biomarkers related to prognosis.
Long non-coding RNAs (lncRNAs) are a class of RNAs lacking protein-coding function which were initially regarded as "junk RNA" [11, 12] . It has been experimentally validated that lncRNAs are involved in the etiology and pathogenesis of various cancers, including BLCA [13] [14] [15] [16] [17] [18] [19] [20] . The recent advances in high-throughput data technologies, including RNAsequencing and microarrays, has guided the identification of lncRNAs for prospective clinical application in BLCA [12, [21] [22] [23] . However, most previous studies focused on the clinical value of individual lncRNAs, which has limited potential for future clinical application. The Cancer Genome Atlas (TCGA) database provides valuable lncRNA data from multiple cancer types, and so it is possible to analyze and discover new lncRNA candidates for the prognostic prediction in BLCA. Previously, Bao et al. [24] reported that a four-lncRNA signature was an independent marker for predicting outcomes in patients with BLCA based on TCGA data acquired in May, 2016. Since then, TCGA data and annotation of lncRNAs have been updated significantly. No differentially expressed lncRNAs (DELs) in BLCA were mentioned by Bao et al. [24] . Moreover, no additional datasets have been used to validate their previous finding either. Therefore, in the current study, DELs were first analyzed from RNA-sequencing data. Next, a prognostic four DEL-based risk score was built up and we further investigated the potential mechanism of these lncRNAs using bioinformatical methodologies (Fig. 1 ).
Materials and Methods
Study population RNA-sequencing reads per kilobase million (RPKM) data of patients with BLCA were obtained from TCGA [12, 25] . The cohort contained 433 samples, including 414 tumor tissue samples and 19 non-tumor adjacent bladder tissue samples. Clinicopathological parameters were also downloaded from TCGA, such as person neoplasm cancer status, successful outcome of primary therapy, pathologic T stage, pathologic N stage, pathologic M stage, pathologic stage, and clinical T stage. After excluding samples without expression data or clinical information, 405 cases and 19 controls remained. Because the dataset was downloaded from TCGA, there was no need to obtain further approval from an ethics committee. The human subject protection and data access policies from TCGA were duly followed when data were processed. 
Construction of a prognostic risk score with DELs
The expression data of each DEL was normalized by using log2 transformation for further analysis. DELs strongly associated with overall survival (OS), with P values lower than 0.05, were identified by univariate Cox proportional hazards regression analysis using the R "survival" package. Next, the prognostic significance of the identified DELs was examined via multivariate Cox proportional hazards regression using SPSS version 22.0 (IBM Corp., Armonk, NY). We constructed a prognostic risk score of DEL signatures for predicting OS according to the summation of the expression data of prognostic DELs multiplied by the regression coefficient from the multivariate Cox regression model (β), described by the formula below:
BLCA patients were then categorized into low-and high-risk groups based on the median of the newly calculated prognostic risk score [28, 29, 31, 32] . The whole process is presented in Fig. 2 .
Moreover, univariate and multivariate Cox proportional hazards regression analyses were carried out to estimate the influence of clinical parameters and the risk score on the OS of BLCA patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were also determined. The predictive analysis of patient outcome was carried out using the receiver operating characteristic (ROC) curve based on the risk scores. KaplanMeier analysis was applied to evaluate the different survival rates for BLCA patients with low-or high-risk scores, and a two-sided log-rank test was utilized to evaluate the differences between the low-and high-risk groups by using SPSS 22.0 software.
Validation of prognostic DELs using other datasets
To verify the expression of the prognostic DELs, DEL expression data from Gene Expression Omnibus (GEO) and ArrayExpress were downloaded and analyzed. The following search terms used were used: (bladder OR urothelial OR urinary OR urogenital) AND (cancer OR carcinoma OR tumor OR neoplasm* OR malignant*) AND (lncRNA OR lncRNAs). Expression data of each DEL from both normal and tumor tissue were extracted and compared using Student's t test with SPSS software.
We performed a meta-analysis to further confirm the expression level of DELs in BLCA tissue.
The pooled standard mean difference (SMD) with 95% CI and publication bias based on TCGA and GEO data were calculated using Stata version 12.0 (StataCorp, College Station, TX). A Begg's funnel plot was also generated.
In addition, we assessed the abundance of the prognostic DELs in other types of tumors, using expression data for the DELs downloaded from Gene Expression Profiling Interactive Analysis (GEPIA, http://gepia.cancer-pku.cn/) to compare of lncRNA expression levels between non-tumor and tumor tissue.
Functional analysis of the selected prognostic DELs
Genes that were co-expressed with the prognostic DELs were obtained from the Multi-Experiment Matrix (MEM) database (http://biit.cs.ut.ee/mem/index.cgi) [33] . Cytoscape and STRING (https://stringdb.org/) were also utilized to visualize the prognostic DELs and their corresponding co-expressed genes as a network [34] [35] [36] [37] [38] .
Potential mechanisms of differentially expressed genes (DEGs) of low-and high-risk groups
As described above, R package edgeR was used to identify DEGs from the low-and high-risk groups, respectively, based on the differential expression analysis between gene expressions of BLCA tissue samples from both groups. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and proteinprotein interaction (PPI) analyses were carried out to complement the functional enrichment analyses of DEGs using the online software DAVID (https://david.ncifcrf.gov/home.jsp, version 6.8). GO enrichment plot and Disease Ontology analysis were performed with the R packages GOplot and DOSE, respectively.
Relationships between DELs and adjacent protein-coding genes
We then evaluated the relationships between the DELs and adjacent protein-coding genes. We identified these adjacent protein-coding genes using the Ensemble Genome Browser. and then downloaded their expression levels, presented as RPKM values, from TCGA. Differential expression analysis of the adjacent protein-coding genes was then performed. Putative relationships between the DELs and their adjacent protein-coding genes were analyzed by using Pearson's correlation coefficient. ROC curve analysis of adjacent protein-coding genes was performed based on TCGA data. All the above statistical analyses were carried out with SPSS software. Statistical significance was confirmed at a P value less than 0.05. Protein expression data of these genes were further subjected to validation using The Human Protein Atlas (THPA; https://www.proteinatlas.org/) [39] ; immunohistochemistry was performed on tissue microarrays for normal bladder and BLCA tissue.
In-house verification of the expression levels of the four lncRNAs and HIST4H4 based on cell lines and

BLCA tissue
To validate the results from big data mining based on the TCGA and GEO datasets, RT-qPCR was utilized to measure the expression levels of AC145124.1, AC010168.2, MIR200CHG, AC098613.1, and HIST4H4 in four BLCA cell lines, including 5637, J82, T24, SW780, and a cell line SV-HUC-1, as well as 15 BLCA tissue samples. These tissue samples were obtained from the First Affiliated Hospital of Guangxi Medical University, the ethics committee of which approved this present study. Written informed consent was obtained from the participants or their family. Total RNA was extracted from cell and tissue samples with total RNA miniprep kit (Magen, R4310-02) and then reversed transcribed into cDNA with the cDNA Synthesis Kit (6110A; Takara, Dalian, China). GAPDH was used as the internal reference. Primers used are as follows: AC145124.1, Forward-5′ -GGCTAACGTAGGCACTCTCG-3′, Reverse-5′-CACTTCTTCCACGAGCACCT-3′; AC010168.2, Forward-5′-TTGGTGTGCAGTTTGGTGTA-3′, Reverse-5′-TAAGTGGTCTGCCCATGTTT-3′; MIR200CHG, Forward-5′-CTGACCAACAACCTCTGACCTTCA-3′, Reverse-5′-AGGCAGCCATTTTGTCTCCTTC-3′; AC098613.1, Forward-5′-CAGGGAGGAAGGTATGTGGT-3′, Reverse-5′-ATCATGTAGGTGCAGGCAGA-3'; HIST4H4, Forward-5'-ATGTGGTGTACGCGCTGAAA-3', Reverse-5′-CGCCAAGTCTAATCCCGAGC-3′; GAPDH, Forward-5′-CTCCAAAATCAAGTGGGGCG-3′, Reverse-5′-TGGTTCACACCCATGACGAA-3′. Relative expression was determined by using the formula: Relative expression = 2 -(Cq gene -Cq GAPDH ) [40, 41] . Analysis of the correlation between AC010168.2 and HIST4H4 expression was performed using SPSS 22.0 software. All statistical tests in the study were two-sided, and a P value less than 0.05 was considered significant. (Fig. 3) .
Results
DELs in
Construction of the prognostic risk score based on DELs
Univariate Cox proportional hazards regression analysis unveiled that 21 DELs among the 1, 095 DELs had prominent prognostic values (P<0.001), which were then used to Fig. 4 ). Subsequently, the risk score used to predict OS was calculated using the following formula: Risk score = EXP AC145124.1 *(-0.105) + EXP AC010168.2 *(-0.427) + EXP MIR200CHG *(-0.181) + EXP AC098613.1 *(-0.173). BLCA patients were classified into two low-and high-risk subgroups based on the median level of the prognostic risk score (Fig. 5) . The survival condition of BLCA patients could reliably be predicted by the risk score, with an AUC value of 0.734 (Fig. 6A) . Furthermore, (Table 3) . However, after multivariate Cox proportional hazards regression analysis, only person neoplasm cancer status, primary therapy outcome success, pathologic stage and risk score were independent prognostic indictors of BLCA (Table 3) . The Kaplan-Meier curves of these survival-associated clinical parameters are displayed in Fig. 7 . The expression levels of the four DELs used to construct the prognostic signature in the low-and high-risk groups are shown in Fig. 8 .
Verification of the four-DELs risk scores using other databases
Two microarrays were obtained from GEO databases based on the inclusion criteria, GSE89006 and GSE51493. However, only the expression data of AC010168.2 and AC098613.1 could be obtained (Fig. 9 ). In the GSE89006 microarray, AC010168.2 expression level in tumor tissue was slightly higher than that in normal tissue (Fig. 9A) , which was consistent with that in TCGA (Fig. 4C) . The expression trend of AC145124.1 in GSE89006 was contradictory with that in TCGA (data not shown). In GSE51493, the expression of AC098613.1 in tumor tissue was slightly higher than that in non-tumor tissue (Fig. 9B) , which was consistent with that in TCGA (Fig. 4G) . However, the expression trend of AC010168.2 in GSE51493 was inconsistent with that in TCGA (data not shown). 
The expression data of only AC010168.2 could be extracted from both GSE51493 and GSE89006. Subsequently, a meta-analysis of AC010168.2 was performed with data from TCGA, GSE51493, and GSE89006 based on 26 non-cancerous controls and 430 BLCA patients. The results showed that the SMD was 0.77 (-0.99, 2.53) (Fig. 10) . Furthermore, heterogeneity tests (I2) showed that P=0.002 with I2 of 83.5% (Fig. 10A ) and one study is outside 95% CI in the Begg's funnel plot (Fig. 10B) . The source of the heterogeneity may come from the different tissue of control group in the three studies. The control group of GSE51493 is the 
normal bladder mucosa tissue while the control groups of TCGA and GSE89006 are both para-carcinoma tissue. This suggests that AC010168.2 expression may differ between normal bladder and paracarcinoma tissue. The expression data of these four lncRNAs in 31 types of tumors from GEPIA indicated that AC145124.1 and AC010168.2 are expressed in almost all tumor types; however, MIR200CHG and AC098613.1 showed no expression in several tumors, such as adrenocortical carcinoma and uterine carcinosarcoma (Fig. 11) . 
The expression of the four lncRNAs in cell lines and BLCA tissue samples assessed in-house
RT-qPCR results showed that the expression of AC145124.1, AC010168.2, MIR200CHG, and AC098613.1 was detected in five cell lines, but at different levels (Fig. 12A) . Since there was only one non-cancerous control cell line, no statistical analysis was possible. Moreover, the expression of the four lncRNAs could also be detected in BLCA tissue samples (Fig. 12B) . Unfortunately, no adjacent tumor tissue could be analyzed due to the specificity of operation strategy.
Network of genes co-expressed with the prognostic DELs
To evaluate the possible function and molecular mechanism of the four prognostic DELs, co-expressed genes were identified from the MEM database (http://biit.cs.ut.ee/mem/). However, data for only the co-expressed genes AC145124.1, AC010168.2, and MIR200CHG could be downloaded. The co-expressed genes AC145124.1, with a score less than 10E-15, Genes not connected to the network are not shown.
Figure 13
Cell Physiol Biochem 2018;50:1474-1495 
Acquisition and functional assessment of DEGs in BLCA between low-and high-risk score groups
DEGs from both the low-and high-risk groups were obtained using the R package edgeR as described above, provided by the BLCA RNA-seq data downloaded from TCGA. DEGs in the low-risk group comprised 1475 genes with P<1E-10, and there were 975 genes with P<1E-10 in the high-risk group. The DEGs were then used for GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The top five GO and KEGG pathways are shown in Tables 4 and 5 and Figures 16 and 17 . There were four common pathways among the top five KEGG pathways, as follows: 'Dilated cardiomyopathy', 'cGMP-PKG signaling pathway', 'Oxytocin signaling pathway', and 'Calcium signaling pathway'. However, the 'Vascular smooth muscle contraction' pathway appeared in the low-risk group while the 'Hypertrophic cardiomyopathy' pathway was identified in the high-risk group.
Disease ontology (DO) analysis showed that DEGs from the high-risk groups were significantly enriched in muscular disease, muscular tissue disease, myopathy, cardiomyopathy, intrinsic cardiomyopathy, muscular dystrophy, hypertrophic cardiomyopathy, and Duchenne muscular dystrophy (Fig. 18) , while the DEGs from the low-risk groups were remarkably enriched in tetralogy of Fallot, glycogen storage disease, and disorders of glycogen metabolism (Fig. 19) .
Potential biological function of the prognostic DEL AC010168.2
We further investigated if there were any protein-coding genes adjacent to the DELs. Interestingly, the protein-coding gene HIST4H4 was found 68 bp upstream of the Genes not connected to the network are hidden.
Figure 14
Cell Physiol Biochem 2018;50:1474-1495 Genes not connected to the network are hidden. Fig. 20B ). The ROC curve revealed that HIST4H4 expression could distinguish BLCA from non-cancerous bladder tissue with an AUC of 0.716 based on TCGA data (Fig. 20C ). Correlation analysis also revealed a positive relationship between AC010168.2 and HIST4H4 levels (Pearson's correlation coefficient = 0.824, P<0.001, Fig. 20D ). In-house real time RT-qPCR showed that HIST4H4 mRNA was expressed at different levels in BLCA cell lines and tissue (Fig.  20E ). However, due to the absence of non-cancerous controls, no statistical analysis could be conducted to compare the expression difference of HIST4H4 mRNA between BLCA and non-cancerous bladder tissue. We also failed to perform prognostic analysis, due to the short time of follow-up. Excitingly, correlation analysis confirmed that the expression of AC010168.2 was significantly positively associated with that of HIST4H4 in BLCA tissue, as assessed by real time RT-qPCR (Fig. 20F ). In addition, the protein expression assessed by immunohistochemistry from THPA database also suggested that HIST4H4 protein tended to be over-expressed in BLCA tissue (Fig. 21, Fig. 22 ) shown with several primary antibodies. However, no other genes adjacent to AC010168.2 were significantly correlated with it 19 . Disease ontology analysis of the differentially expressed genes (DEGs) from the low-risk groups. P values represent the degree of enrichment. The count is the number of genes involved in the disease. Gene Ratio is the ratio between the number of selected genes for a disease and the total number of genes in the DO analysis. The degree of enrichment is represented by the rich factor, which is the ratio between the number of selected genes for a term and the total number of genes in the analysis. The size of each node indicates the total number of genes involved and the color reflects the P value from the enrichment analysis. Note: GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; CC, cellular component; MF, molecular function; BP, biological process. 
Discussion
First, due to the contributions of TCGA RNA-sequencing data, DELs in BLCA were identified in BLCA in this study, which was followed by univariate and multivariate Cox regression analyses. It is noteworthy that the risk score based on four novel DELs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) could accurately predict the prognosis of BLCA patients. Furthermore, we found that distinct signaling pathways may exert their functions in the low-and high-risk groups. Lastly, a protein-coding gene, HIST4H4 was found just 68 bp from one of the DELs, AC010168.2. The expression of HIST4H4 was positively correlated with that of AC010168.2 in BLCA patients. This in silico investigation thereby pioneers the future investigation of prognostic lncRNAs for BLCA.
Prognostic lncRNAs have been previously reported by Bao et al. [24] , who found that four lncRNAs, AC005682.5, CTD-2231H16.1, CTB-92J24.2, and RP11-727F15.13 could form a signature to predict survival in BLCA. Because the amount of data on BLCA patients in both TCGA and lncRNA datasets has been greatly expanded, we were able to perform this innovative investigation. Surprisingly, all four lncRNA candidates in our current study were different from those found by Bao et al. [24] . Compared to the previous study by Bao et al. [24] , there are several advantages of the present study which need to be highlighted. First, Bao et al. [24] identified prognostic lncRNAs in a training group with 117 cases, then validated those lncRNAs in another subset of the cases as a testing group (n=117) as well as with the entire group (n=234). The data were downloaded in May of 2016. The present study covers a total of 414 BLCA patients, and 317 cases had sufficient data to identify novel prognostic lncRNAs, which thereby enlarges the sample size of inquiry. Second, our prognostic lncRNAs were discovered from 317 cases, a much larger cohort than that of Bao et al. [24] , which provides more convincing results. Third, cohorts with alternative detection approaches (i.e., microarray) were used for validation in the current study, which further strengthens the current findings, as Bao et al. [24] had only a single cohort from TCGA. Even though we failed to perform meta-analyses for all four of these lncRNAs, in-house RT-qPCR could detect the expression of the lncRNAs both in BLCA cell lines and clinical samples. Fourth, the number of identified lncRNAs increased from 12730 to 13199 in the present study; 469 more new lncRNAs were found. More importantly, updated lncRNA annotations may have changed the known attributes of genes. One typical example is the lncRNA CTD-2231H16.1 from the study of Bao et al. [24] , which has been excluded in the newly updated GENCODE. Fifth, before the prognostic evaluation, we screened out DELs that were inconsistent with the findings of Bao et al. [24] . If lncRNAs exerted little effect on carcinogenesis, their prognostic significance would be decreased. We investigated the prognostic value of the four DELs based on the evidence that they were differentially expressed between BLCA and non-cancerous bladder tissue. Accordingly, the four DELs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) in the current study served as indicators of not only the stage of tumorigenesis, but also the process of deterioration. Sixth, Bao et al. [24] did not exclude patients with short survival times. In contrast, we only included patients whose survival time was longer than 90 days, as those with shorter survival times probably died of causes other than the cancer itself. Seventh, we attempted to explain the underlying molecular mechanism of these lncRNAs by performing signaling pathway analyses to compare the low-and high-risk groups. Lastly, adjacently located protein-coding genes were identified with the Ensemble Genome Browser. Thus, compared to the previous report, the current study yields more powerful and comprehensive data, showing that the four DELs AC145124.1, AC010168.2, MIR200CHG, and AC098613.1 can collectively be an independent prognostic indicator for BLCA patients.
DEGs from the high-and low-risk groups were enriched in different diseases, contributing to the differential prognosis of patients in high-and low-risk groups. We noticed that when patients with BLCA were separated into low-and high-risk groups based on their four DELsrisk score, their DEGs and related signaling pathways were distinguishable. For instance, KEGG analysis found the pathway 'vascular smooth muscle contraction' only in the low-risk group, and 'muscular disease, muscular tissue disease, myopathy, cardiomyopathy' was found using DO analysis. In contrast, pathways related to 'hypertrophic cardiomyopathy' was found in the high-risk group by KEGG analysis and 'tetralogy of Fallot, glycogen storage disease and glycogen metabolism disorder' were enriched in DO analysis. To gain a better understanding of these DELs in BLCA, we also searched for protein-coding genes adjacent to the DELs. Fascinatingly, we found the protein-coding gene HIST4H4 68bp upstream of the DELsAC010168.2. Importantly, the clinical value of HIST4H4 in BLCA was observed at both the mRNA and protein levels, and it is positively correlated the expression level of AC010168.2 as shown both RNA-seq data from TCGA and in-house RT-qPCR validation. Hence, we hypothesize that the novel lncRNA AC010168.2 may modulate the expression of the protein-coding gene HIST4H4, or they could collaborate through some unknown interaction to affect the survival of BLCA patients.
LncRNAs are RNAs of more than 200 nucleotides in length, which have no coding structure. At present, several mechanisms of lncRNA activity have been discovered. LncRNAs exert their functions via various mechanisms by binding to DNA, RNA, or proteins at the cellular level. At the transcriptional level, lncRNAs are able to direct the course of correction of the guide chromatin remodeling complexes to the appropriate chromosomal positions, thus regulating the equilibrium between transcriptionally active chromatin and Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry silent heterochromatin in both local and global conditions. In addition, lncRNAs are capable of inhibiting or facilitating the recruitment of RNA pol II, transcription factors, and/or cofactors to gene promoters, thus modulating the transcription of their target genes. Posttranscriptionally, lncRNAs have the capacity to adjust alternative splicing of pre-mRNAs and hence display functions of transcriptomic complexity. Additionally, lncRNAs can influence the stability and translation of mRNA via base pairing with mRNA molecules. It has also been well-documented that lncRNAs can act as competing endogenous RNAs (ceRNAs) to participate in the competition for miRNA binding, thus stopping their activity and affecting the translation of miRNA target genes. Furthermore, lncRNA can also be programmed into small, single-, or double-stranded RNAs, which may cause target mRNA degradation, similar to the function of small interfering RNAs. Moreover, the flexible scaffold nature of lncRNAs enables them to combine multiple protein factors that cannot collaborated or interfere through only protein-protein interactions. The scaffold effect of lncRNAs also plays an essential part in protein activity, localization, and subcellular structure formation [42, 43] . In the current study, we identified four survival-associated lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) from the DELs in TCGA and built a prognostic signature with the four lncRNAs to predict the prognosis of BLCA patients. Among these four lncRNAs, the noteworthy up-regulated expression of AC010168.2, MIR200CHG, and AC098613.1 was observed in tumor than in non-tumor tissue, unlike that of AC145124.1. The up-regulated lncRNAs protective actions may be partially explained by the various functional mechanisms of lncRNAs described above. For example, up-regulated AC010168.2, MIR200CHG, and AC098613.1 in BLCA may act as ceRNAs to competitively bind miRNAs and thereby inhibit the function of miRNAs to enhance the expression of miRNA target genes, which may include tumor suppressors. However, this hypothesis needs to be validated in a series of rigorous experiments.
There are some deficiencies in the current work that need to be addressed. First, the sequencing data from TCGA contained a small control group of only 19 tumor-free adjacent normal bladder tissue samples. Although we attempted to utilize microarray data from GEO, performed in-house RT-qPCR detection, and performed a meta-analysis, the current findings still need to be validated with a larger sample size. Second, we did not perform a prognostic analysis with our own clinical samples due to the lack of sufficient follow-up information. A larger sample size with longer follow-up is required in the future. Third, none of the four lncRNAs identified in the current study have been reported in the literature, and so the functions of these lncRNAs remain entirely unknown. Finally, a series of rigorous experiments is needed to uncover the roles of these four lncRNAs in BLCA.
Conclusion
In conclusion, four novel lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) were used to generate a valuable risk score, which can serve as an independent indicator to predict the survival status of BLCA patients due to their influences on distinct signaling pathways. This in silico study may pioneer future exploration into the study of prognostic lncRNAs in BLCA.
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